Question 1

What are the most cited papers from Amplimmune (United States)?

Accepted Answer

The most cited paper from Amplimmune (United States) is "New use of BCG for recombinant vaccines" (C. Kendall Stover, Vidal F. de la Cruz, Thomas R. Fuerst et al., 1991), with 1,513 citations. Next come "Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus" (647) and "CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade" (481).

Question 2

Which research topics does Amplimmune (United States) publish most on?

Accepted Answer

By volume in 2022-now: Pharmacogenetics and Drug Metabolism, Computational Drug Discovery Methods, Receptor Mechanisms and Signaling and CAR-T cell therapy research.

Question 3

Which keywords describe research at Amplimmune (United States)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Epidemiology, Monoclonal Antibodies, Therapeutic Antibodies, Glycosylation, Tumor Microenvironment, Inflammation, Immunotherapy and Immunity.

Question 4

Which fields of science does Amplimmune (United States) work in?

Accepted Answer

In all years, 48% of research at Amplimmune (United States) is in Health Sciences, 43% in Life Sciences. Its largest fields are Medicine (46%), Biochemistry, Genetics and Molecular Biology (22%), Immunology and Microbiology (17%). It does 2.4× the world's share of Life Sciences.

Question 5

Is Amplimmune (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 91% lower than in 2018-2021.